{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:30:22Z","timestamp":1792639822607,"version":"4.5.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Aggressive adult T-cell leukemia\/lymphoma (ATL) is a hematological malignancy that is difficult to treat with chemotherapy alone, and allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapy. We conducted a multicenter, prospective, observational study to clarify the treatment outcomes of aggressive ATL in the current era. Between 2015 and 2018, 113 patients aged 70 years or younger with newly diagnosed aggressive ATL were enrolled. The median age at diagnosis was 61 years. Treatment outcomes were compared with those of 1792 ATL patients diagnosed between 2000 and 2013 in our previous retrospective study. The inclusion criteria were the same in both studies. The prospective cohort demonstrated better overall survival (OS) than the retrospective cohort (2-year OS, 45% vs 29%, respectively; P &amp;lt; .001), with a much higher proportion of patients receiving allo-HCT (80% vs 34%, respectively; P &amp;lt; .001) and a shorter interval from diagnosis to allo-HCT (median, 128 vs 170 days, respectively; P &amp;lt; .001). Among the 90 patients who received allo-HCT (cord blood, n = 30; HLA-haploidentical related donors, n = 20; other related donors, n = 14; other unrelated donors, n = 26), the 2-year probabilities of OS, non-relapse mortality (NRM), and disease progression were 44%, 23%, and 46%, respectively. OS and NRM did not differ statistically according to donor type. Our results suggest that increased application of allo-HCT improved the survival of patients with aggressive ATL. The use of cord blood or HLA-haploidentical donors may be feasible for aggressive ATL when HLA-matched related donors are unavailable. This study was registered at the UMIN Clinical Trials Registry as #000017672.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021004932","type":"journal-article","created":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T21:46:36Z","timestamp":1631223996000},"page":"4156-4166","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":31,"title":["Improved survival of patients with aggressive ATL by increased use of allo-HCT: a prospective observational study"],"prefix":"10.1182","volume":"5","author":[{"given":"Ayumu","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Nakano","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imamura General Hospital, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-0850","authenticated-orcid":false,"given":"Takashi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5118-7950","authenticated-orcid":false,"given":"Shigeo","family":"Fuji","sequence":"additional","affiliation":[{"name":"Department of Hematology, Osaka International Cancer Institute, Osaka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0883-2920","authenticated-orcid":false,"given":"Junya","family":"Makiyama","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, Institute of Medical Science, The University of Tokyo Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilseung","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohisa","family":"Nakamae","sequence":"additional","affiliation":[{"name":"Hematology, Graduate School of Medicine, Osaka City University, Osaka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nagafuji","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Kurume University Hospital, Kurume, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Takase","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Machida","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Tokai University Hospital, Isehara, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-3469","authenticated-orcid":false,"given":"Tsutomu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shimane University Hospital, Izumo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sawayama","sequence":"additional","affiliation":[{"name":"Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kamimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Harasanshin Hospital, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4896-5878","authenticated-orcid":false,"given":"Masao","family":"Ogata","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oita University Hospital, Oita, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5528-7112","authenticated-orcid":false,"given":"Souichi","family":"Shiratori","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hokkaido University Hospital, Sapporo, Japan; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Uchimaru","sequence":"additional","affiliation":[{"name":"Department of Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Inamoto","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[{"name":"Department of Hematology, Imamura General Hospital, Kagoshima, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"issue":"34","key":"2021102215241190200_B1","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol."},{"issue":"24","key":"2021102215241190200_B2","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood."},{"issue":"9","key":"2021102215241190200_B3","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol."},{"issue":"8","key":"2021102215241190200_B4","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021102215241190200_B5","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol."},{"issue":"3","key":"2021102215241190200_B6","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","article-title":"Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study","volume":"3","author":"Ogura","year":"2016","journal-title":"Lancet Haematol."},{"issue":"34","key":"2021102215241190200_B7","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","article-title":"Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002","volume":"34","author":"Ishida","year":"2016","journal-title":"J Clin Oncol."},{"issue":"3","key":"2021102215241190200_B8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12185-018-02588-5","article-title":"JSH Practical Guidelines for Hematological Malignancies, 2018: II. Lymphoma-8. Adult T-cell leukemia-lymphoma","volume":"109","author":"Tsukasaki","year":"2019","journal-title":"Int J Hematol."},{"issue":"8","key":"2021102215241190200_B9","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood."},{"issue":"12","key":"2021102215241190200_B10","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.bbmt.2014.08.012","article-title":"Treatment of patients with adult T cell leukemia\/lymphoma with cord blood transplantation: a Japanese nationwide retrospective survey","volume":"20","author":"Kato","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2021102215241190200_B11","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/cas.13398","article-title":"Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey","volume":"108","author":"Nosaka","year":"2017","journal-title":"Cancer Sci."},{"issue":"8","key":"2021102215241190200_B12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult T-cell leukemia-lymphoma international consensus meeting report","volume":"37","author":"Cook","year":"2019","journal-title":"J Clin Oncol."},{"issue":"7","key":"2021102215241190200_B13","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.3324\/haematol.2017.164996","article-title":"Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger: possible risk-adapted management strategies including allogeneic transplantation","volume":"102","author":"Fuji","year":"2017","journal-title":"Haematologica."},{"issue":"8","key":"2021102215241190200_B14","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/s41409-018-0400-5","article-title":"A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma","volume":"54","author":"Yoshimitsu","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"2021102215241190200_B15","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12185-012-1177-8","article-title":"Unrelated cord blood transplantation for patients with adult T-cell leukemia\/lymphoma: experience at a single institute","volume":"96","author":"Nakamura","year":"2012","journal-title":"Int J Hematol."},{"issue":"4","key":"2021102215241190200_B16","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s12185-013-1307-y","article-title":"Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia\/lymphoma: a retrospective analysis of the Nagasaki Transplantation Network","volume":"97","author":"Fukushima","year":"2013","journal-title":"Int J Hematol."},{"issue":"3","key":"2021102215241190200_B17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol."},{"issue":"12","key":"2021102215241190200_B18","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2021102215241190200_B19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","article-title":"Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research","volume":"15","author":"Giralt","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2021102215241190200_B20","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant."},{"issue":"3","key":"2021102215241190200_B21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"key":"2021102215241190200_B22","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","author":"Japan Clinical Oncology Group (JCOG)"},{"issue":"3","key":"2021102215241190200_B23","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"2021102215241190200_B24","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/bmt.2015.330","article-title":"Analysis of non-relapse mortality and causes of death over 15 years following allogeneic hematopoietic stem cell transplantation","volume":"51","author":"Tanaka","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"2021102215241190200_B25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood."},{"issue":"28","key":"2021102215241190200_B26","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol."},{"issue":"1","key":"2021102215241190200_B27","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/hon.2558","article-title":"The outcome and characteristics of patients with relapsed adult T cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation","volume":"37","author":"Kato","year":"2019","journal-title":"Hematol Oncol."},{"issue":"2","key":"2021102215241190200_B28","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41409-018-0291-5","article-title":"Safety of mogamulizumab for relapsed ATL after allogeneic hematopoietic cell transplantation","volume":"54","author":"Inoue","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"5","key":"2021102215241190200_B29","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator\u2019s choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Phillips","year":"2019","journal-title":"Haematologica."},{"issue":"2","key":"2021102215241190200_B30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/hon.2712","article-title":"Treatment with mogamulizumab or lenalidomide for relapsed adult T-cell leukemia\/lymphoma after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience","volume":"38","author":"Sakamoto","year":"2020","journal-title":"Hematol Oncol."},{"issue":"4","key":"2021102215241190200_B31","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12185-019-02675-1","article-title":"Complete response following toxic epidermal necrolysis in relapsed adult T cell leukemia\/lymphoma after haploidentical stem cell transplantation","volume":"110","author":"Morishige","year":"2019","journal-title":"Int J Hematol."},{"issue":"6","key":"2021102215241190200_B32","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/leu.2012.352","article-title":"Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia","volume":"27","author":"Pfeifer","year":"2013","journal-title":"Leukemia."},{"issue":"11","key":"2021102215241190200_B33","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1158\/1078-0432.CCR-13-3169","article-title":"CADM1 expression and stepwise downregulation of CD7 are closely associated with clonal expansion of HTLV-I-infected cells in adult T-cell leukemia\/lymphoma","volume":"20","author":"Kobayashi","year":"2014","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2021102215241190200_B34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-021-00458-8","article-title":"Quantification of T cell clonality in human T cell leukaemia virus type-1 carriers can detect the development of adult T cell leukaemia early","volume":"11","author":"Wolf","year":"2021","journal-title":"Blood Cancer J."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/20\/4156\/1830027\/advancesadv2021004932.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/20\/4156\/1830027\/advancesadv2021004932.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T15:25:42Z","timestamp":1634916342000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/20\/4156\/476851\/Improved-survival-of-patients-with-aggressive-ATL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":34,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,10,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021004932","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]}}}